Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Zacks Investment Research on MSN

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $385.74, moving +1.01% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.59% ...
pharmaphorum

Vertex islet cell therapy gets type 1 diabetics off insulin

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...